Fatty acid‐binding protein‐3 and renal function decline in patients with chronic coronary syndrome

Abstract

AbstractBackgroundRenal dysfunction is common in patients with coronary artery disease. Due to the shared vascular pathogenesis between the two conditions, novel biomarkers such as the fatty acid‐binding protein‐3 (FABP‐3) have been proposed for diagnosis and prognosis prediction. This multicentre prospective cohort study investigates the association between FABP‐3 and renal dysfunction.HypothesisWe hypothesized that higher FABP‐3 levels are correlated to worse renal outcome.MethodsPatients with chronic coronary syndrome were classified into three groups based on the initial serum FABP‐3 levels. The Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI) equation was used to estimate the patient's renal function. Renal events were defined as >25% and >50% decline in estimated glomerular filtration rate (eGFR). Cox multivariable regression was employed to delineate the correlation between FABP‐3 and renal dysfunction.ResultsA total of 1606 subjects were included. During a mean follow‐up of 35.9 months, there were 239 patients with eGFR >25% reduction and 60 patients with >50% reduction. In the Kaplan–Meier survival curve and log‐rank test, increased levels of FABP‐3 were significantly correlated with eGFR >25% reduction (p < .001) and >50% reduction (p < .001). Multivariate Cox regression model revealed that subjects with higher FABP‐3 exhibited a greater risk of eGFR >25% reduction (Group 2: hazard ratio [HR] = 2.328, 95% confidence interval [CI] = 1.521–3.562, p < .001; Group 3: HR = 3.054, 95% CI = 1.952–4.776, p < .001) and >50% reduction (Group 3: HR = 4.838, 95% CI = 1.722–13.591, p = .003).ConclusionsSerum FABP‐3 may serve as a novel biomarker to predict eGFR decline in patients with chronic coronary syndrome.